At Nanomug we harness the power of nature’s defense mechanisms by developing a revolutionary drug delivery platform based on glycosylated mucin nanoparticles. This innovative technology redefines pharmaceutical development through API repurposing and by maximizing targeting and mucoadhesivity, ultimately delivering unmatched therapeutic solutions.
Our platform seamlessly integrates synthesis, drug encapsulation, and functionalization into a single-step process, optimizing both targeting and mucoadhesivity for enhanced performance. Capable of encapsulating a diverse range of bioactive compounds—from small molecules to proteins—our mucosomes achieve high entrapment efficiency. Engineered with sustainability in mind, our technology utilizes mucin derived from food industry by-products, minimizes solvent use, reduces waste, and provides a scalable, cost-effective solution for pharmaceutical innovation.
Our vision is to become the strategic partner of choice for the pharmaceutical market, offering versatile, high-impact solutions in infectious diseases, oncology, and other mucosal health applications. Through relentless innovation, we empower our partners to deliver breakthrough therapies that transform healthcare and improve patient outcomes.
Company Details
- Employees
- 3
- Address
- Via Nizza, 44, Turin,piedmont 10125,italy
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.nanomug.it/
- HQ
- Turin, Piedmont
Nanomug Questions
Nanomug's website is https://www.nanomug.it/
Nanomug's LinkedIn profile is https://it.linkedin.com/company/nanomug
Nanomug has
3 employees.
View email and phone details for 3
employees at Nanomug.
Nanomug's industry is
Biotechnology Research
Nanomug's top competitors are
Kither Biotech,
Checkmab S.r.l.,
Genenta Science (Nasdaq: Gnta),
Clepio Biotech,
Iama Therapeutics,
Genesys Biologics,
Resalis Therapeutics,
Sibylla Biotech,
Eubiome,
Altheia Science.
Nanomug's categories are Biotechnology Research
